Watch Pfizer Inc for free: we tell you when fair value or trend changes.

Pfizer Inc (PFE) fair value: what the stock is really worth

As of Oct 21, 2026: fair value (intrinsic value) of Pfizer Inc stock $24.87, price $29.85, upside -16.7%, quality 60 out of 100. Rating: overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

Fair value above price? No
Good quality? Yes
Add to watchlist

Healthcare · US · ISIN US7170811035

Broad data Oct 22, 2026

Pfizer Inc

PFE · US

Overvalued / MonitorQuality is not strong enough to offset the price risk.

Our calculation puts a fair price 17% below what the stock costs today.

Quality 60/100

Generates free cash flow

Broad data

Mixed Growth (revenue 5y +8.5 %/yr in USD)

Thin margins · 6.8% net margin (TTM)

Moderate debt

5.8% dividend yield · Payout strained

Mixed vs. peers (6/14)

Moderate moat 54/100

Fair value $24.87 · Overvalued (−16.7%)

Insider activity 35/100

26 models, one by oneBear $14.50 to bull $37.49 Growth analysisrevenue history, year by year Quality 60/100 in detail37 factors, each one shown Compared with its peersrank on every measure, side by side

Watch Pfizer Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 22, 2026.

How to read this chart

60‑month range $19.46 – $47.42 · fair‑value band $14.50 – $37.49 · the $29.85 price screens above the $24.87 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Oct 22, 2026.

Follow Pfizer in your weekly email

Every Wednesday you see whether Pfizer is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite.

Show moreShow less

The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands.

In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands.

Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin.

The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models.

Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Stock analysis

Pfizer Inc (PFE) currently trades at $29.85, while our model-based Fair Value estimate is $24.87, 16.7% below the price, so the stock looks overvalued today.

Valuation

Bull case: the Multiples group reads highest at a median of $29.99 per share, and 6 of the 23 models we run sit above the $29.85 price.

Bear case: the Economic Profit group reads lowest at $14.82, and 17 of the 23 models stay below the price. Data coverage for this calculation is high.

Scenario range: $14.50 (bear) to $37.49 (bull), the price of $29.85 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 60/100 (solid quality), in the Healthcare sector.

Mixed Growth: Spin-off in 2020: revenue and profit before it include the divested business. Growth is measured afresh from 2020.

Pfizer Inc reported revenue of $62.6B in FY2025 versus $81.3B in FY2021, a compound −6.3%/yr. Reported net income was $7.8B in FY2025, compounding −23.0%/yr from FY2021.

Key figures

Market cap $170B Large · P/E ratio 39.3 · P/S ratio 2.67 · EPS (TTM) $0.7600 · Dividend yield 5.8% · Net margin 6.8% · Return on equity 5.0% · Return on assets (EBIT) 9.6%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 54 out of 100 (medium confidence).

What moves the price

The last reported earnings sit well below what analysts expect (earnings in transition, for example after write-downs or an earnings dip); whether the stock is cheap or expensive hinges on the expected recovery actually arriving. Read the fair value with that caveat.

The share trades about 1% below its 52-week high and 32% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −3% fair-value upside, at −17%, PFE screens richer than that median.

Fair Value models

Bear $14.50 Fair Value $24.87 Bull $37.49

Price $29.85 · Upside -16.7%

Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.

Best data coverage

FCF DCF $13.68 $26.82 $47.94 74

EPV $14.99 $19.71 $23.98 74

Residual Income $13.47 $14.82 $17.83 74

All 23 models by family

DCF Models

FCF DCF $13.68 $26.82 $47.94 74

Owner Earnings $8.00 $18.06 $34.22 70

5Y Revenue Exit $12.09 $24.58 $40.13 68

5Y EBITDA Exit $21.43 $41.45 $64.18 71

5Y P/E Exit $10.79 $22.23 $33.76 67

10Y Revenue Exit $11.70 $23.38 $38.21 62

10Y EBITDA Exit $18.55 $35.37 $56.76 64

10Y P/E Exit $11.58 $21.71 $33.31 60

Earnings-Based

Graham-Dodd $9.27 $23.81 $30.99 63

PEG = 1.0 $4.47 $6.38 $8.29 55

EPV $14.99 $19.71 $23.98 74

Dividend Discount

Gordon GGM $17.18 $36.65 $70.54 62

DDM Multi-Stage $17.18 $27.25 $39.12 64

Multiples

P/E Multiple $22.49 $29.99 $37.49 63

P/S Multiple $17.38 $23.18 $28.97 58

EV/EBIT $22.90 $34.42 $45.93 65

EV/EBITDA $28.95 $42.48 $56.01 66

EV/Revenue $11.43 $21.31 $31.19 52

Growth DCF

Growth DCF $14.50 $26.74 $45.52 73

Rev-Margin DCF $12.09 $24.74 $38.58 68

Economic Profit

Residual Income $13.47 $14.82 $17.83 74

ROIC Compounder $14.99 $21.82 $30.68 69

Growth Earnings

Growth-Adj P/E $17.41 $24.87 $32.33 65

Open the full fair value analysis →

Quality Score breakdown

Overall quality 60/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 37

How much profit the company makes from its sales and capital

Quality Growth 43

Are margins and returns getting better?

Cashflow 68

Do the profits arrive as real cash?

Financial strength 43

Debt, balance sheet and risk of trouble

Investment 93

Does it invest with discipline instead of growing at any price?

Low Volatility 93

How calm the share price moves, does not count

Momentum 64

Price trend of the last 3 to 12 months, does not count

Near the 52-week high 81

Distance to the 52-week high, does not count

New shares 81

Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 55/100

Spin-off in 2020: revenue and profit before it include the divested business. Growth is measured afresh from 2020.

Revenue growth 1 year

−1.6%

Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

−14.6%

Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+8.5%

Start year 2020 (pandemic)

’14

’15

’16

’17

’18

’19

’20

’21

’22

’23

’24

’25

What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.

−7.1%

Earnings growth per share plus dividend.

Earnings per share, growth per year−12.9%

Dividend (yield on the price)5.8%

Per share before 2020divided by the spin-off factor 1.054

Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−12.9% vs −13.1%, steady

Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.22% → 25%

Pace: the 5-year rate starts in 2020 (pandemic)

⚠ Revenue per share shrinking 11.3%/yr over ~10Y (margins eroding too) ⓘStructural-decline marker: revenue PER SHARE has fallen over the last decade (robust median trend, not a single year). Backtested across 2005 to 2017, such businesses trailed the market by about 2.5 percentage points per year. Display only: it does not change the fair value or the quality score.

Growth Forecast

A lot of optimism in the price

The price assumes about as much growth as the company has delivered so far and more than analysts expect.

What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).

+8.5%

Yearly growth needed for the next five years to justify today's price.

What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.

−2.4%

Yearly sales growth analysts expect, extended to five years.

After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +6.0% a year for the price and −4.7% for the forecasts.

Forecast 2026 (sales)−0.6%

Forecast 2027 (sales)−4.0%

Projected 2028 (sales)−3.2%

Projected 2029 (sales)−2.5%

Projected 2030 (sales)−1.7%

PFE screens overvalued: fair value 17% below the price. Compare with Eli Lilly and Company →

Note from the team Oct 11, 2026

AI conclusion: Pfizer shows oncology momentum from the TUKYSA approval yet faces an average moat with limited innovation differentiation and below-average returns on equity and assets.

Main risk: Elevated leverage relative to equity risks constraining funding for the post-COVID pipeline shift and obesity programs.

Pfizer just secured FDA approval to expand TUKYSA into front-line maintenance for HER2+ metastatic breast cancer. That adds oncology momentum as the company shifts focus to its broader pipeline and obesity programs after the COVID era. Our models see it as overvalued, so will the new indications and catalysts deliver enough growth to close the gap or will execution risks keep the valuation in check?

Join the discussion →

Compare Pfizer Inc with another stock

Price, fair value, quality and upside side by side.

First stock

Second stock

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - General · 74 stocks

Beats the industry median on 6/14 measures

A mixed picture versus its industry peers.

Valuation

Quality Score 60 · Above median

Fair Value upside −16.7% · Below median

Profitability

Return on equity (12 months) 5.0% · Below median

Return on assets 3.7% · Below median

Net margin (12 months) 6.8% · Below median

Operating margin (12 months) 27.9% · Above median

Growth and dividend

Revenue growth (quarter YoY) 2.6% · Below median

Dividend yield (12 months) 5.8% · Top 25%

Balance sheet

Debt / equity 0.70× · Highest 25%

Valuation Multiplesvs Drug Manufacturers - General median · lower = cheaper

P/E (12 months) 39.3× · Priciest 25%

P/B 1.97× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.

P/S (12 months) 2.67× · Cheaper than median

Price / free cash flow 18.7× · Cheaper than median

EV/EBITDA 9.1× · Cheaper than median

PEG 12.89× · Priciest 25%

Strength profile in five axes (Snowflake)

This stock

Sector peers

VALUE (fair-value potential)11 · sector 22

FUTURE (revenue growth)13 · sector 31

PAST (return on equity)20 · sector 40

HEALTH (low debt)65 · sector 92

DIVIDEND (yield)100 · sector 40

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - General stocks, each showing price versus our Fair Value estimate.

Stock	Price	Fair Value	vs Fair Value	Compare
Sanofi SNY	$40.97	$70.57	+72%	vs PFE
Gilead Sciences, Inc GILD	$156.51	$198.77	+27%	vs PFE
Bristol-Myers Squibb Company BMY	$61.68	$75.96	+23%	vs PFE
Amgen Inc AMGN	$438.94	$482.83	+10%	vs PFE
Novartis AG NOVN	CHF 124.20	CHF 120.24	−3%	vs PFE
AbbVie Inc ABBV	$289.08	$259.62	−10%	vs PFE
Merck & Co MRK	$148.30	$129.26	−13%	vs PFE
Roche Holding RO	CHF 385.60	CHF 326.56	−15%	vs PFE
Johnson & Johnson, JNJ	$259.36	$168.85	−35%	vs PFE
Eli Lilly and Company LLY	$1,284	$749.40	−42%	vs PFE

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued High-Quality Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks Undervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark

Run the numbers yourself: free valuation calculators

DCF Calculator P/E Ratio Calculator PEG Ratio Calculator Graham Number Peter Lynch Formula DDM Calculator Intrinsic Value Intrinsic vs Extrinsic Value P/E Ratio by Sector

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Pfizer Inc · Fair Value
$24.87 −17%Fair Value
Calculator →

<a href="https://www.fairvalue-calculator.com/stock/PFE" target="_blank" rel="nofollow noopener" style="display:inline-flex;align-items:center;gap:12px;box-sizing:border-box;font-family:system-ui,-apple-system,Segoe UI,Roboto,sans-serif;text-decoration:none;background:#0f1814;color:#eaf2ed;border:1px solid #2a3a30;border-radius:12px;padding:12px 16px;max-width:360px"><span style="line-height:1.35"><span style="font-size:12px;color:#9fb0a8">Pfizer Inc · Fair Value</span><br><b style="font-size:20px">$24.87</b> <span style="color:var(--red);font-weight:700;font-size:14px">−17%</span></span><span style="font-size:11px;color:var(--fvc-g-mitte);font-weight:700;margin-left:auto;text-align:right;line-height:1.3">Fair&nbsp;Value<br>Calculator&nbsp;→</span></a>

Cite: Fair Value Calculator (2026). "Pfizer Inc Fair Value". https://www.fairvalue-calculator.com/stock/PFE

Frequently asked questions

Is Pfizer Inc (PFE) overvalued or undervalued?

As of Oct 22, 2026, our model estimates a fair value of $24.87 versus a price of $29.85, about −17% upside (overvalued).

What is the fair value of PFE?

Our model-based fair value for Pfizer Inc is $24.87 (as of Oct 22, 2026), built from audited fundamentals. The current price: $29.85.

What is the quality score of PFE?

Pfizer Inc has a Quality Score of 60/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.

What is the price target for Pfizer Inc (PFE)?

Our model-based price target is the fair value of $24.87 (as of Oct 22, 2026) from 23 valuation models. Cautious scenario $14.50, optimistic scenario $37.49. It is a calculation from audited fundamentals, not an analyst target.

What is the Pfizer Inc stock forecast for 2026?

Our models put fair value at $24.87, about −17% upside versus a price of $29.85 (overvalued). Cautious scenario $14.50, optimistic scenario $37.49. The calculation is refreshed regularly with new filings.

What is the revenue of Pfizer Inc (PFE)?

Pfizer Inc reported trailing-twelve-month revenue of about $63.7B (latest available figure, as of Oct 22, 2026).

Does Pfizer Inc pay a dividend?

Pfizer Inc currently shows a dividend yield of 5.76% relative to its recent price (as of Oct 22, 2026).

What growth is priced into Pfizer Inc (PFE)?

For today's price to be fair in a discounted-cash-flow model, Pfizer Inc would have to grow free cash flow by +8.5 % per year for five years (discount rate 8.1 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +8.5 % per year. As of Oct 22, 2026.

What discount rate (WACC) does the fair value of PFE use?

Our models discount Pfizer Inc at 8.1 %: a base by market capitalisation (large), damped by beta 0.30, country premium for USA. The same rate applies in all 26 models.

What is a reverse DCF?

A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Pfizer Inc that is +8.5 % per year a year over ten years, using the same discount rate (8.1 %) and the same formula as our fair value.

How much growth has Pfizer Inc (PFE) delivered so far?

Over the past 5 years revenue at Pfizer Inc grew +8.5 % a year. The price currently implies +8.5 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.

How fast is the sector of Pfizer Inc (PFE) growing?

The median revenue growth in the sector is +5.6 % a year. That is the yardstick for the growth priced into Pfizer Inc (+8.5 % per year a year): it shows whether the expectation is within the usual range or beyond it.

What is the free cash flow yield of Pfizer Inc (PFE)?

The free-cash-flow yield on the price is 5.34 %: that much free cash flow Pfizer Inc produces per unit of market value. When it exceeds the discount rate of our models (8.1 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.

What is the intrinsic value of Pfizer Inc (PFE)?

Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Pfizer Inc it is $24.87 per share (as of Oct 22, 2026), against a price of $29.85. It is the blended result of 23 valuation models (cash flow, earnings, asset, dividend).

Is Pfizer Inc stock overvalued or undervalued in 2026?

As of Oct 22, 2026, PFE trades above its calculated fair value: price $29.85, fair value $24.87, a gap of about −17% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.

Is fair value the same as the market price of PFE?

No. The price is what the market pays today ($29.85); the fair value is what the company's own numbers justify ($24.87). For Pfizer Inc the two are $4.98 per share apart. That gap is exactly why we show both numbers side by side.

How much is Pfizer Inc worth?

The market values Pfizer Inc at about $170B (market capitalisation, as of Oct 22, 2026). Per share that is $29.85; our models calculate a fair value of $24.87 per share.

What do the bullish and bearish scenarios say about PFE?

Our models span a range for Pfizer Inc: cautious scenario $14.50, base $24.87, optimistic $37.49 per share (as of Oct 22, 2026, price $29.85). The range comes from different growth and margin assumptions, not from analyst opinions.

What is the P/E ratio of PFE?

Pfizer Inc trades at a price-to-earnings ratio of 39.3 (as of Oct 22, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $24.87 is built from several models across several years. Median P/E at fiscal year-end, 6 fiscal years (2020 to 2025), reported earnings: 18.5. Other multiples: PEG 12.9, P/B 2.0, P/S 2.7, EV/EBITDA 9.1.

What is the PEG ratio of PFE?

The PEG ratio of Pfizer Inc is 12.89 (P/E divided by earnings growth, as of Oct 22, 2026). That is above 1, so the growth is already paid for in the price.

How solid is the balance sheet of Pfizer Inc (PFE)?

Balance-sheet figures for Pfizer Inc (as of Oct 22, 2026): return on equity 5.0%, debt of 0.70 per unit of equity. They feed the Quality Score of 60/100, which measures business quality independently of the share price.

How far is PFE from its 52-week high?

Pfizer Inc trades at $29.85, about 1% below its 52-week high of $30.11 and 32% above the low of $22.70 (as of Oct 21, 2026). Distance from the high says nothing about value: that is what the fair value of $24.87 is for.

Which stocks are comparable to Pfizer Inc?

From the same area (Healthcare) we also value Eli Lilly and Company, Johnson & Johnson,, AbbVie Inc, Roche Holding, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.

Is Pfizer Inc stock attractive at the current price?

The data as of Oct 22, 2026: price $29.85, calculated fair value $24.87 (−17%), Quality Score 60/100, from 23 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.

How is the fair value of PFE calculated?

We run Pfizer Inc through 23 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $24.87, with the spread shown as a cautious and an optimistic scenario.

Is it still worth investing in stocks now?

The global stock market currently sits 13.6 % above its aggregate fair value. Pfizer Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.

What is the share price of Pfizer Inc (PFE)?

The closing price on Oct 21, 2026 was $29.85. Our model-based fair value is $24.87, about −17% upside (overvalued). We carry closing prices from our data provider, not a live tick.

What should I pay attention to with Pfizer Inc right now?

Solid but not exceptional quality (60/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range ($14.50 to $37.49) leaves room in how you read the outcome.

Key figures of Pfizer Inc

How large is the market capitalisation of Pfizer Inc (PFE)?

The market capitalisation of Pfizer Inc is $170B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.

What is the P/S ratio of Pfizer Inc (PFE)?

The price-to-sales ratio of Pfizer Inc is 2.67 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.

What are the earnings per share of Pfizer Inc (PFE)?

Earnings per share at Pfizer Inc are $0.7600 (price ÷ EPS = P/E 39.3). Earnings per share over the last twelve months: total profit spread across every single share.

What is the dividend yield of Pfizer Inc (PFE)?

The dividend yield of Pfizer Inc is 5.8%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.

What is the net margin of Pfizer Inc (PFE)?

The net margin of Pfizer Inc is 6.8% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.

What is the return on equity of Pfizer Inc (PFE)?

The return on equity (ROE) of Pfizer Inc is 5.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.

What is the EBIT return on assets of Pfizer Inc (PFE)?

On an EBIT basis the return on assets of Pfizer Inc is 9.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.

What is the operating margin of Pfizer Inc (PFE)?

The operating margin of Pfizer Inc is 27.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.

How fast is revenue growing at Pfizer Inc (PFE)?

Revenue at Pfizer Inc is growing +2.6% versus a year earlier (3y avg −14.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.

How fast are earnings growing at Pfizer Inc (PFE)?

Earnings per share at Pfizer Inc are growing −10.1% versus a year earlier. How much earnings per share grew versus a year earlier.

How much net debt does Pfizer Inc (PFE) carry?

The net debt of Pfizer Inc is $66.3B (fiscal year 2025, ≈ 7.3 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.

Free · no account needed

Watch Pfizer Inc in the live analysis

One click puts Pfizer Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.